Monocytic and neutrophilic CD11b and CD64 in severe sepsis

Jämsä, Joel; Huotari, Virva; Savolainen, E.–R.; Syrjälä, Hannu; Ala‐Kokko, T. I.

doi:10.1186/cc11728

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Typical neutrophil receptors such as CD11b and CD66b are both elevated during sepsis but represent different mechanisms for inflammation. Explicitly, CD11b may also be found on monocytes, natural killer cells, and macrophages, participating in cell adhesion and migration in the presence of CD18 (Jämsä et al, 2012). On the other hand, CD66b, also known as carcinoembryonic antigen‐related cell adhesion molecule 8 (CEACAM8), is involved in adhesion but also in altering neutrophil migration patterns as higher levels (Schmidt et al, 2012).…”

Section: Sepsis Biomarkers Used In Point‐of‐critical‐care Sensorsmentioning

confidence: 99%

Point‐of‐critical‐care diagnostics for sepsis enabled by multiplexed micro and nanosensing technologies

Ashley

Hassan

2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Sepsis is responsible for the highest economic and mortality burden in critical care settings around the world, prompting the World Health Organization in 2018 to designate it as a global health priority. Despite its high universal prevalence and mortality rate, a disproportionately low amount of sponsored research funding is directed toward diagnosis and treatment of sepsis, when early treatment has been shown to significantly improve survival. Additionally, current technologies and methods are inadequate to provide an accurate and timely diagnosis of septic patients in multiple clinical environments. For improved patient outcomes, a comprehensive immunological evaluation is critical which is comprised of both traditional testing and quantifying recently proposed biomarkers for sepsis. There is an urgent need to develop novel point‐of‐care, low‐cost systems which can accurately stratify patients. These point‐of‐critical‐care sensors should adopt a multiplexed approach utilizing multimodal sensing for heterogenous biomarker detection. For effective multiplexing, the sensors must satisfy criteria including rapid sample to result delivery, low sample volumes for clinical sample sparring, and reduced costs per test. A compendium of currently developed multiplexed micro and nano (M/N)‐based diagnostic technologies for potential applications toward sepsis are presented. We have also explored the various biomarkers targeted for sepsis including immune cell morphology changes, circulating proteins, small molecules, and presence of infectious pathogens. An overview of different M/N detection mechanisms are also provided, along with recent advances in related nanotechnologies which have shown improved patient outcomes and perspectives on what future successful technologies may encompass. This article is categorized under: Diagnostic Tools > Biosensing

show abstract

Section: Sepsis Biomarkers Used In Point‐of‐critical‐care Sensorsmentioning

confidence: 99%

Point‐of‐critical‐care diagnostics for sepsis enabled by multiplexed micro and nanosensing technologies

Ashley

Hassan

2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Specifically, CD11b participates in cell adhesion and migration in the presence of CD18. 35 Contrastingly, CD66b (or CEACAM8) is involved in adhesion but also in altering neutrophil migration patterns at higher levels. 36 Both are currently measured using fluorescence labels or antibody-specific immunoassays and are promising new sepsis biomarkers.…”

Section: Introductionmentioning

confidence: 99%